Margaret K Callahan

13PUBLICATIONS
148CO-AUTHORS
Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Medical biotechnology diagnostics (incl. biosensors)Cancer therapy (excl. chemotherapy and radiation therapy)Chemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Apr 09, 2025
The response to anti-PD-1 and anti-LAG-3 checkpoint blockade is associated with regulatory T cell reprogramming.

Annah S Rolig, Xiyu Peng, Elizabeth R Sturgill

|Feb 26, 2025
Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020.

Paolo A Ascierto, Hao Tang, Sonia Dolfi

|Jun 14, 2024
Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichment.

Adam J Widman, Minita Shah, Amanda Frydendahl

|May 20, 2024
Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study.

James W Smithy, Hannah L Kalvin, Fiona D Ehrich

|Feb 05, 2024
Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032).

Margaret Callahan, Asim Amin, Frederic J Kaye

|Nov 06, 2023
Phase Ib Trial of Phenformin in Patients with V600-mutated Melanoma Receiving Dabrafenib and Trametinib.

Paul B Chapman, Mark Klang, Michael A Postow

Pageof 3

Frequent Collaborators

7 joint publications

Jedd D Wolchok

5 joint publications

Matthew Adamow

5 joint publications

Alexander Noor Shoushtari

4 joint publications

Taha Merghoub